Participant flow

An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting · Source last updated 2018-06-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4. Palonosetron Dexamethasone

   id

   FG000

   title

   I.V. Palonosetron Infusion Plus Dexamethasone

2. description

   Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4. Palonosetron Dexamethasone

   id

   FG001

   title

   I.V. Palonosetron Bolus Plus Dexamethasone

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         225

      2. group Id

         FG001

         num Subjects

         215

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         218

      2. group Id

         FG001

         num Subjects

         206

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         7

      2. group Id

         FG001

         num Subjects

         9

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice